SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
SEC Accession No. 0001193125-10-246426
Filing Date
2010-11-04
Accepted
2010-11-03 18:12:02
Documents
9
Period of Report
2010-09-30
Filing Date Changed
2010-11-03

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q d10q.htm 10-Q 640447
2 COLLABORATION AGREEMENT dex101.htm EX-10.1 580517
3 AMENDMENT NO. 1 TO LICENSE AGREEMENT dex102.htm EX-10.2 39309
4 CERTIFICATION OF CHIEF EXECUTIVE OFFICER dex311.htm EX-31.1 6173
5 CERTIFICATION OF CHIEF FINANCIAL OFFICER dex312.htm EX-31.2 6167
6 CERTIFICATION OF CHIEF EXECUTIVE OFFICER dex321.htm EX-32.1 3643
7 CERTIFICATION OF CHIEF FINANCIAL OFFICER dex322.htm EX-32.2 3638
8 GRAPHIC g107472g20k22.jpg GRAPHIC 12066
9 GRAPHIC g107472g42i30.jpg GRAPHIC 2110
  Complete submission text file 0001193125-10-246426.txt   1301171
Mailing Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037
Business Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037 (858) 875-8600
Orexigen Therapeutics, Inc. (Filer) CIK: 0001382911 (see all company filings)

IRS No.: 651178822 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33415 | Film No.: 101162626
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1